Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

7.765 +0.715 (+10.14%)
Streaming Delayed Price Updated: 3:45 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
News headline image
Compass Pathways Plc (CMPS) Q1 2024 Earnings Call Transcript ↗
CMPS earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
CMPS Stock Earnings: Compass Pathways Misses EPS for Q1 2024 ↗
CMPS stock results show that Compass Pathways missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May ↗
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD. 
Via Talk Markets
News headline image
Jim Cramer Slams Political Blocking Of 'LSD-Derived Antidepressants,' Citing Strong Test Data 'Showing They Worked' ↗
 
Via Benzinga
News headline image
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 29, 2024 ↗
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
News headline image
Earnings Preview For Compass Pathways ↗
 
Via Benzinga
News headline image
Who's Who In Cannabis: Latest Executive Changes You Should Know About ↗
 
Via Benzinga
News headline image
The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD ↗
The pharmaceutical industry is embracing AI to streamline drug discovery and researching the use of psychedelic compound-based ingredients for the treatment of, as yet, untreatable diseases. 
Via Talk Markets
Topics Artificial Intelligence
News headline image
Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTD ↗
The 5 constituents in the Psychedelic Compound-Based Drug Stocks Index were up 10.0%, on average, last week and are now up 53.9% YTD. 
Via Talk Markets
News headline image
Micron, Iris Energy, Trip.com Group And Other Big Stocks Moving Higher On Monday ↗
U.S. stocks were lower, with the Dow Jones falling around 250 points on Monday. 
Via Benzinga
Topics Stocks
News headline image
March Recap: Largest Psychedelic Drug Stocks Up Another 5% ↗
The 5 constituents in the munKNEE Psychedelic Compound-Based Drug Stocks Index were UP 5.4%, on average, in March and are now UP 39.9% YTD. 
Via Talk Markets
News headline image
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More ↗
 
Via Benzinga
News headline image
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence ↗
 
Via Benzinga
News headline image
Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline ↗
 
Via Benzinga
News headline image
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More ↗
 
Via Benzinga
Topics Economy
The Next Great Biotech Boom Has Arrived
EQNX::TICKER_START (NYSE:JNJ),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:ATAI),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement ↗
 
Via Benzinga
News headline image
Psychedelic Compound-Based Drug Stock, Mind Medicine, Up 56% Last Week ↗
The FDA has granted breakthrough designation to Mind Medicine's program for the treatment of generalized anxiety disorder. 
Via Talk Markets
News headline image
MindMed Receives FDA 'Breakthrough Therapy' Designation For LSD As Anxiety Treatment, Shares Positive Results About Related Clinical Trials ↗
 
Via Benzinga
News headline image
Psychedelics 2024: Veterans Blessing, Mental Health Paradigm Shift, Providers Training, Ketamine-MDMA Bonds & More ↗
 
Via Benzinga
News headline image
3 Biopharma Stocks You Don't Want to Miss in the New Bull Market ↗
All three have exciting programs on the way. 
Via The Motley Fool
News headline image
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More ↗
 
Via Benzinga
News headline image
Largest Psychedelic Compound-Based Drug Stocks Up 15% In February; Now Up 33% YTD ↗
The Psychedelic Compound-Based Drug Stocks Index was up 15.0% in February led by Incannex Healthcare which was up 55.1%. 
Via Talk Markets
News headline image
Compass Pathways Plc (CMPS) Q4 2023 Earnings Call Transcript ↗
CMPS earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
News headline image
Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment ↗
 
Via Benzinga
News headline image
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results. 
Via Benzinga
News headline image
Podcast - Post-Frenzy Psychedelics Investing And Reclaiming The Right To Pursue Happiness With Zappy Zapolin: '2024 Is When It Goes Mainstream' ↗
 
Via Benzinga
News headline image
Penny Power Players: 3 Stocks to Watch in the Microcap Arena ↗
Dive into three microcap stocks set to skyrocket with innovative strategies and sector leadership. Don't miss out. 
Via InvestorPlace
News headline image
Mental Health Mavericks: 3 Stocks Changing the Game ↗
Except for the psychedelics movement, there seem to be very few mental health stocks to buy that are making money. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.